Trial Profile
Multi-Center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2019
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors American Regent; Luitpold Pharmaceuticals
- 26 Jun 2014 New trial record